The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV) entered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the South African B.1.351 variant, also known as 501Y.V2.
CEPI is an international coalition set up to prepare for future infectious disease threats.
It will provide up to $33 million to support the advancement of VBI-2905, a monovalent eVLP candidate, through Phase 1 development. Phase 1 trial will start in mid-year 2021.
As part of the agreement, this funding will also support the preclinical expansion of additional multivalent vaccine candidates.
VBI Vaccines is advancing a suite of coronavirus vaccine candidates under the VBI-2900 program, developed in collaboration with the National Research Council of Canada.
An adaptive Phase 1/2 study of VBI-2902 is already ongoing at nine clinical sites in Canada.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.